[ad_1]

  • Atara Biotherapeutics Inc ATRA completed the planned Interim Analysis of the ATA188 Phase 2 study (EMBOLD) in progressive multiple sclerosis patients.
  • The analysis’ primary focus was on expanded disability status scale (EDSS) improvement at six months and overall safety, and also included evaluation of EDSS beyond six months for patients. 
  • The analysis was also designed to assess if a sample size increase was needed. It was planned to occur before enrolling patient 80 to enable an increased sample size if needed.
  • EDSS improvement appeared to be predictive of improvement at 12 months. 
  • Also See: Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics.
  • There was no sufficient dataset to draw conclusions about the predictive value of six months EDSS improvements for 12 months.
  • The safety monitoring committee believes the six-month interim endpoint may be an inaccurate measure. It recommended continuing the study without sample size adjustment until the final analysis.
  • The final read-out of the study’s primary endpoint of confirmed EDSS improvement at 12 months is planned for October 2023.
  • Price Action: ATRA shares are down 52% at $4.16 during the premarket session on the last check Wednesday.

[ad_2]

Source link